On September 1, 2026, Adena Health acquired Fairfield Medical Center (FMC), an Ohio hospital that has served Fairfield County for over 110 years. But this was not the deal FMC originally pursued. FTC staff, working with the Ohio Attorney General, had challenged an earlier acquisition proposed by OhioHealth, which would have given it a significant share of inpatient admissions in the region.

Two FTC statements accompanied the announcement one from Bureau of Competition Director Daniel Guarnera, and one from Chairman Andrew Ferguson (joined by Commissioner Mark Meador).1 Together, they offer the clearest window yet into how the agency evaluates sale processes when a financially distressed hospital seeks a buyer.

Hospitals pursuing strategic transactions should take note: the FTC expects a broad, good-faith search for buyers, documented from the start. A truncated process will not support a failing firm defense and may prompt the agency to demand a do-over or litigate.

Rather than sue to block the deal, FTC staff pushed FMC to run a broader process. The result: multiple interested buyers, abandonment of the OhioHealth transaction and a new partnership with Adena Health. Because Adena does not operate in Fairfield County, the FTC says the outcome preserves competition.

The shop process as a gating requirement

Chairman Ferguson was direct: "financial distress is not a blank check for mergers that would substantially reduce competition.” An otherwise anticompetitive acquisition is justifiable “only if the distressed firm can substantiate that its 'shop' process engaged with other buyers that do not present similar competition concerns."

Under longstanding Supreme Court precedent, restated in the 2023 Merger Guidelines, a failing firm defense requires: (1) a "grave probability of a business failure"; (2) “dim or nonexistent” prospects of reorganizing in bankruptcy; and (3) after a good-faith effort to obtain other offers, the proposed buyer "is the only available purchaser."2 As the Chairman put it, "[t]he mere fact . . . that a close competitor is willing to buy the financially distressed hospital is not sufficient to justify an otherwise unlawful risk of harm to patients and healthcare workers."3

The five factors staff will examine

The specifics vary, but FTC staff generally examine:

  1. Whether the search solicited interest from all potential buyers.
  2. Whether buyers had sufficient time to evaluate the opportunity.
  3. Whether buyers received equal access to necessary information.
  4. Whether the seller engaged with interested buyers in good faith.
  5. Whether the seller seriously considered offers from buyers without competitive concerns.

Bottom line: an adequate search is a prerequisite to any failing firm argument. And if that search turns up a buyer that would preserve competition, the seller cannot choose the anticompetitive bidder just because it offers more money.

Consequences of an inadequate process

The FTC expects sellers to document outreach so staff can review it quickly. If the process falls short, then the agency may force a re-shop, as it did here, or litigate. Director Guarnera warned: "The standard is demanding, and if you have not searched broadly for a buyer, we will work expeditiously with firms to investigate whether there is a better buyer and, if the Commission deems it necessary, go to court to block a bad deal."

Historical context

The FTC has long viewed financial-distress defenses with skepticism. Former Bureau of Competition Director Ian Conner warned that parties invoking the defense had "better actually be failing, and able to prove it."4 The agency has also cautioned about "miraculous recoveries”-- supposedly failing firms that rebounded after deals fell through-- and has said that counsel who overuse the defense may face extra scrutiny.5

The focus on shop adequacy is not new. In 2015, Bureau officials warned that “something more than a 'perfunctory' search for an alternative purchaser is necessary” and that the FTC would, in some cases, require an adequate search before deciding not to challenge a transaction.

What distinguishes Fairfield Medical Center is the specificity of the FTC's guidance, particularly the five-factor framework. The same logic applies to “flailing firm” arguments, where a hospital is struggling but not on the brink of closure. There too, a thorough, well-documented search will be essential.

Key takeaways

  • The shop process is a gating requirement. A narrow process will not pass muster if broader outreach would have surfaced a less problematic buyer.
  • Engage the full universe of buyers. Approaching a single or preferred buyer is insufficient. Non-competitors must be included.
  • Money is not a defense. A higher anticompetitive bid cannot trump a pro-competitive offer.
  • Document from day one. Reconstructing the process after the fact will not work.
  • Re-shopping is a real risk. The FTC will demand that sellers re-run an inadequate process.
  • State AGs are co-enforcers. Deal strategy must account for state enforcement risk.
  • Litigation remains a live threat. The negotiated outcome here should not be mistaken for a signal that the FTC will always prefer a consensual resolution.

The Fairfield Medical Center matter did not result in litigation or a consent order, but it is a significant enforcement signal. The FTC has laid out its clearest expectations yet for how a financially distressed hospital should shop itself: run a broad, documented process from the start or be prepared to do it over.

Companies engaged in hospital M&A should consult with antitrust counsel regarding the FTC’s heightened expectations for sale processes and any financial-distress-based arguments.

Footnotes

  1. 1

    See Daniel Guarnera, Dir., Bureau of Competition, Fed. Trade Comm'n, FTC Bureau of Competition Director Statement Regarding Fairfield Medical Center's Sale to Adena Health (Sept. 2, 2026), Statement Regarding Fairfield Medical Center’s Sale to Adena Health; Statement of Chairman Andrew N. Ferguson, Joined by Commissioner Mark R. Meador, Regarding Fairfield Medical Center's Sale to Adena Health, Fed. Trade Comm'n (Sept. 2, 2026) (hereinafter the “Ferguson Statement”), Statement of Chairman Andrew N. Ferguson Joined by Commissioner Mark R. Meador Regarding Fairfield Medical Center’s Sale to Adena Health.

  2. 2

    Int'l Shoe Co. v. FTC, 280 U.S. 291 (1930); U.S. Dep't of Justice & Fed. Trade Comm'n, Merger Guidelines § 3.1, at 30 (2023) (hereinafter “Merger Guidelines”), 2023 Merger Guidelines.

  3. 3

    Ferguson Statement, supra note 1.

  4. 4

    Ian Conner, Bureau of Competition, Fed. Trade Comm'n, On "Failing" Firms — and Miraculous Recoveries, Competition Matters Blog (May 27, 2020), On “Failing” Firms — and Miraculous Recoveries.

  5. 5

    Debbie Feinstein & Alexis Gilman, Bureau of Competition, Fed. Trade Comm'n, Power Shopping for an Alternative Buyer, Competition Matters Blog (Mar. 31, 2015), Power shopping for an alternative buyer.

Contact